Zydus Lifesciences Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ZYDUSLIFE.NS | MANKIND.BO | 009420.KS | WOCKPHARMA.BO | ZTS | 1795.TW | |
|---|---|---|---|---|---|---|
| Market cap | 1.13T | 915.72B | 2.04T | 292.69B | 33.45B | 45.96B |
| P/E (TTM) | 25.2 | 44.9 | — | 71.5 | 13.3 | 12.1 |
| Forward P/E | 22.8 | 31.3 | — | — | 12.6 | 7.3 |
| Price/book | 4.2 | 5.6 | — | 6.0 | 10.6 | 1.9 |
| Dividend yield | 0.09% | — | — | — | 2.59% | 1.49% |
| 1-year change | +12.95% | −6.37% | +20.66% | +39.52% | −43.81% | −38.58% |
| Today | −0.49% | −2.63% | −0.25% | −2.96% | −1.29% | −1.99% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 20 min.
Latest news
All ZYDUSLIFE.NS news ›Zydus Lifesciences gets USFDA nod for menopause treatment drug
Zydus Lifesciences Ltd on Wednesday said it has received the final approval from the US health regulator to market a generic transdermal system for treatment of moderate to severe symptoms of menopause and prevent postmenopausal…
Zydus Lifesciences Subsidiary Zylidac Bio Partners With Prolific Machines For Biologics Production
Positive strategic momentum in expanding complex biologics CDMO capacity, backed by USD 75 million investment in US biomanufacturing assets and key regulatory progress. On October 13, 2026, Zydus Lifesciences and Formycon AG announced that…
Zydus Lifesciences Secures USFDA Final Approval for Menopause Treatment Patch with USD 45.7 Million US Sales
New Delhi: Zydus Lifesciences Limited (Zydus) has announced that the United States Food and Drug Administration (USFDA) has granted final approval for its Abbreviated New Drug Application (ANDA) for Estradiol and Levonorgestrel Transdermal…
Zydus Lifesciences Gets USFDA Approval for Hormone Patch
Authored By HDFC SKY | Published at: Oct 21, 2026 12:12 PM IST Zydus Lifesciences has received final USFDA approval for its estradiol and levonorgestrel transdermal system, which is eligible for 180-day Competitive Generic Therapy…
Zydus Lifesciences' Moraiya Plant Receives 5 USFDA Observations
Ahmedabad: The US Food and Drug Administration (USFDA) has concluded an inspection of Zydus Lifesciences Limited's manufacturing plant at Moraiya in Ahmedabad, Gujarat, with five observations. The inspection was conducted from October 5 to…
Zydus Lifesciences announces $20 million investment for pharmaceutical facility in Sri Lanka
Zydus Lifesciences invests over $20 million for a new pharmaceutical facility in Sri Lanka. Zydus Lifesciences announces $20 million investment for pharmaceutical facility in Sri Lanka Zydus Lifesciences Limited, in conjunction with…
Zydus Lifesciences Sri Lanka Plant: USD 20 Million JV Deal
Kalkine India Zydus Lifesciences (NSE:ZYDUSLIFE): Is It Building a Plant in Sri Lanka? Source: Krish Capital Pty Ltd Zydus Lifesciences Limited (NSE:ZYDUSLIFE) disclosed on 15 October 2026 that its proposed joint venture entity, Zydus…
Zydus Lifesciences JV signs $20m Sri Lanka pharma facility deal
Zydus Lifesciences Limited, through its joint venture with Sunshine Healthcare, has signed an agreement with the Board of Investment (BOI) of Sri Lanka to establish a pharmaceutical manufacturing facility. The project involves a phased…
Zydus Lifesciences Keytruda Biosimilar FYB206 Accepted For USFDA Review
FYB206 is the first Keytruda biosimilar candidate accepted for USFDA review, positioning Zydus Lifesciences and licensing partner Formycon AG to enter North America's multi-billion-dollar oncology market upon approval. Market snapshot:…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
sahi.com5
-
businessupturn.com4
-
medicaldialogues.in4
-
business-standard.com2
-
thehindubusinessline.com2
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 27 articles, not a forecast.